Biocompatible di-block-polymer based nanocarrier
Technology
Biocompatible di-block-polymer based nanocarrier enabling improved cancer diagnostics and treatment.
Market
Diagnostics and treatment of cancer – theranostics.
Uniqueness
- Allowing for systemic delivery.
- Unique prospective capture of daughter radionuclides near the emission site empowers less off-target effects.
- Enabling multiple and various tumor-targeting ligands.
- Biodegradable.
Status
- Ra-223 and Cu-64 binding and stability tests performed with high standards.
- Biodistribution analyses ongoing.
- In vivo efficacy models to be run Q1/2026.
- Two patent application filed. National continuations, February 2024, in a broad portfolio of international jurisdictions.
- Seeking commercial partners and licensees.
